![]() |
Name |
Scopularide B
|
Molecular Formula | C34H53N5O7 | |
IUPAC Name* |
(3S,6S,9R,12S,19S)-3-benzyl-19-hexan-2-yl-6-methyl-9-(2-methylpropyl)-12-propan-2-yl-1-oxa-4,7,10,13,16-pentazacyclononadecane-2,5,8,11,14,17-hexone
|
|
SMILES |
CCCCC(C)[C@@H]1CC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O1)CC2=CC=CC=C2)C)CC(C)C)C(C)C
|
|
InChI |
InChI=1S/C34H53N5O7/c1-8-9-13-22(6)27-18-28(40)35-19-29(41)39-30(21(4)5)33(44)37-25(16-20(2)3)32(43)36-23(7)31(42)38-26(34(45)46-27)17-24-14-11-10-12-15-24/h10-12,14-15,20-23,25-27,30H,8-9,13,16-19H2,1-7H3,(H,35,40)(H,36,43)(H,37,44)(H,38,42)(H,39,41)/t22?,23-,25+,26-,27-,30-/m0/s1
|
|
InChIKey |
HVPYLVISSBODEY-AQVZVHCSSA-N
|
|
Synonyms |
SCOPULARIDE B; CHEMBL465774
|
|
CAS | NA | |
PubChem CID | 24899413 | |
ChEMBL ID | CHEMBL465774 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 643.8 | ALogp: | 4.9 |
HBD: | 5 | HBA: | 7 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 172.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 46 | QED Weighted: | 0.258 |
Caco-2 Permeability: | -5.407 | MDCK Permeability: | 0.00007090 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.948 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.109 |
30% Bioavailability (F30%): | 0.667 |
Blood-Brain-Barrier Penetration (BBB): | 0.046 | Plasma Protein Binding (PPB): | 85.45% |
Volume Distribution (VD): | 0.409 | Fu: | 3.63% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.02 |
CYP2C19-inhibitor: | 0.162 | CYP2C19-substrate: | 0.06 |
CYP2C9-inhibitor: | 0.356 | CYP2C9-substrate: | 0.027 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.057 |
CYP3A4-inhibitor: | 0.896 | CYP3A4-substrate: | 0.17 |
Clearance (CL): | 4.623 | Half-life (T1/2): | 0.454 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.758 |
Drug-inuced Liver Injury (DILI): | 0.177 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.526 | Maximum Recommended Daily Dose: | 0.194 |
Skin Sensitization: | 0.064 | Carcinogencity: | 0.026 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.075 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002514 | ![]() |
0.939 | D0J7XL | ![]() |
0.360 | ||
ENC002373 | ![]() |
0.604 | D09OOV | ![]() |
0.331 | ||
ENC004731 | ![]() |
0.542 | D0L7LC | ![]() |
0.327 | ||
ENC005276 | ![]() |
0.530 | D02SBQ | ![]() |
0.319 | ||
ENC005273 | ![]() |
0.518 | D0X9PF | ![]() |
0.316 | ||
ENC005275 | ![]() |
0.503 | D02XIY | ![]() |
0.306 | ||
ENC003950 | ![]() |
0.466 | D09ZIO | ![]() |
0.303 | ||
ENC005272 | ![]() |
0.454 | D0D8XY | ![]() |
0.301 | ||
ENC005274 | ![]() |
0.444 | D0M3FJ | ![]() |
0.300 | ||
ENC005271 | ![]() |
0.441 | D0M2YE | ![]() |
0.298 |